Baxter Expands Injectable Product Line
Baxter debuts 5 injectables in 2024 for infections, cancer, GERD, antibacterial use, and seizures.
Baxter International Inc. has announced five new injectable pharmaceutical product launches in the U.S., bringing their total to 10 for 2024. The recent additions include Micafungin for Candida infections, Cyclophosphamide for malignant diseases, Pantoprazole Sodium for GERD and hypersecretion conditions, Cefazolin in a new strength for antibacterial use, and Levetiracetam for seizure therapy.
These ready-to-use formats aim to improve healthcare efficiency by simplifying preparation processes, reducing contamination risks, and enhancing patient safety. These products are now available in the U.S. for healthcare providers.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion